Premium
Infliximab chimaeric anti‐tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes
Author(s) -
Stasi Roberto,
Amadori Sergio
Publication year - 2002
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2002.03279.x
Subject(s) - infliximab , myelodysplastic syndromes , medicine , bone marrow , tumor necrosis factor alpha , monoclonal antibody , necrosis , immunology , monoclonal , antibody , cancer research
Summary. Tumour necrosis factor alpha (TNF‐α) is believed to play a major role in apoptotic death of bone marrow cells in myelodysplastic syndromes (MDS). We explored the efficacy and safety profile of infliximab chimaeric anti‐TNF‐α monoclonal antibody treatment in two MDS patients. They both had low‐/intermediate‐risk MDS, isolated anaemia and elevated circulating levels of TNF‐α. Infliximab produced no adverse side‐effects and resulted in sustained erythroid responses, one major and one minor. Laboratory studies indicated a remarkable decrease in the percentage of apoptotic stem cells in the bone marrow. This preliminary report indicates that infliximab may have an application as MDS therapy and warrants further investigation.